AIHealthcare

Orakl Oncology is a French precision-oncology techbio company and spin-off from the Gustave Roussy Institute, combining patient-derived tumor organoids, real-world clinical data, genomic, transcriptomic and phenotypic data, automation, and machine learning to support cancer drug discovery and development. Its platform creates patient tumor avatars to model drug response, identify therapeutic targets and biomarkers, evaluate drug combinations, and help biopharma companies de-risk clinical trials. The company markets AI-powered solutions including O-Predict for forecasting clinical responses and trial outcomes, and O-Validate for target, biomarker, and causal biology validation. It initially focuses on colorectal and pancreatic cancers and positions itself at the intersection of AI, advanced biology, and precision oncology, serving pharmaceutical and biotechnology companies and collaborating with hospitals and research institutions.